Valerie Morisset
Fondatore presso ELIEM THERAPEUTICS, INC.
Patrimonio netto: 3 M $ in data 30/06/2024
Profilo
Valerie Morisset is the founder of Eliem Therapeutics, Inc., where she currently holds the title of Chief Scientific Officer, EVP & Head-R&D.
She founded the company in 2018.
Dr. Morisset is also the founder of Convergence Pharmaceuticals Ltd.
Additionally, Dr. Morisset is currently the Director at Eliem Therapeutics (UK) Ltd.
In the past, she worked as a Principal at GlaxoSmithKline LLC and as a Venture Partner at Bridge Valley Ventures LLP from 2018 to 2019.
Dr. Morisset completed her graduate degree at Université de Bordeaux.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
ELIEM THERAPEUTICS, INC.
0.67% | 05/07/2024 | 450 614 ( 0.67% ) | 3 M $ | 30/06/2024 |
Posizioni attive di Valerie Morisset
| Società | Posizione | Inizio |
|---|---|---|
| ELIEM THERAPEUTICS, INC. | Fondatore | 18/10/2018 |
Eliem Therapeutics (UK) Ltd.
 Eliem Therapeutics (UK) Ltd. BiotechnologyHealth Technology Eliem Therapeutics (UK) Ltd. is based in Altrincham, UK. Part of RA Capital Management LP, Eliem Therapeutics (UK) Ltd. is a British company that engages in research and development on biotechnology. Founded in 2019. | Direttore/Membro del Consiglio | 18/12/2019 |
Precedenti posizioni note di Valerie Morisset
| Società | Posizione | Fine |
|---|---|---|
Bridge Valley Ventures LLP
 Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures LLP is a Venture Capital firm founded in 2017. Bridge Valley Ventures LLP is headquartered in Cambridge. | Corporate Officer/Principal | 01/03/2019 |
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Fondatore | 01/01/2018 |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Corporate Officer/Principal | - |
Formazione di Valerie Morisset
| Université de Bordeaux | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ELIEM THERAPEUTICS, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Health Technology |
Convergence Pharmaceuticals Ltd.
Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Convergence Pharmaceuticals Ltd. develops novel analgesics for the treatment of chronic pain. It provides CNV1014802, a small molecule state-dependent sodium channel blocker; and CNV1061436, a sodium channel blocker for the treatment of central nervous system disorders, including epilepsy and bipolar disorder. The company was founded by Brenda Reynolds in September 2010 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Bridge Valley Ventures LLP
Bridge Valley Ventures LLP Investment ManagersFinance Bridge Valley Ventures LLP is a Venture Capital firm founded in 2017. Bridge Valley Ventures LLP is headquartered in Cambridge. | Finance |
Eliem Therapeutics (UK) Ltd.
Eliem Therapeutics (UK) Ltd. BiotechnologyHealth Technology Eliem Therapeutics (UK) Ltd. is based in Altrincham, UK. Part of RA Capital Management LP, Eliem Therapeutics (UK) Ltd. is a British company that engages in research and development on biotechnology. Founded in 2019. | Health Technology |
- Borsa valori
- Insiders
- Valerie Morisset
